In Brief: Furness in new CDER role; Oxytrol for Women at retail; advisories on drug-tainted sex enhancers; senators want energy drink restrictions
This article was originally published in The Tan Sheet
Executive Summary
Furness takes on new CDER role; Merck’s Oxytrol OTC arrives at retail; FDA issues advisory on drug-tainted sex enhancers; senators want energy drink restrictions; more news In Brief.
You may also be interested in...
Ingredient Safety Concerns Rise Among FDA Enforcement Priorities
Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.
FSMA Supplier Verification Rule Affects Finished Supplement Importers
Proposed FSMA rules would subject imported food products, including supplements, to the same safety standards as domestically produced food. The proposals are reminders that although supplement manufacturing is exempt from FSMA provisions redundant to GMP requirements, the act adds regulatory burdens for some firms.
In Brief
FDA seeks DMAA product seizure; skin tag remover study flawed – ERSP; Plan B One-Step approved fully OTC; FDA continues evaluating laxative TEA; FDA hosts supply chain public hearing; energy drink marketing to youths challenged; more news In Brief.